Edaravone is a novel free radical scavenger and was the first neuroprotective agent that was clinically used for the treatment of acute cerebral infarction. In May 2017, US FDA is approved Edaravone for the treatment of amyotrophic lateral sclerosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properties, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects.
